Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is characterized by a high rate of metastasis ...

A 41-year-old Dunwoody mom who never smoked a day in her life was diagnosed with terminal stage 4 lung cancer.

The combination of telisotuzumab vedotin and erlotinib did not lead to any unexpected safety signals and showed encouraging antitumor activity in patients with EGFR-mutated, c-Met protein expressing ...

Findings from this phase 2 trial support further study of erlotinib as "an effective, acceptable cancer preventive agent for FAP-associated gastrointestinal polyposis," the study team says.

The FDA has approved Cyramza (ramucirumab; Lilly) in combination with erlotinib, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have ...

(HealthDay News) — Overdosing of erlotinib may be associated with rapid onset of conjunctivitis, according to a case report published online Oct. 25 in the Journal of Clinical Pharmacy and ...

Erlotinib was first approved more than a decade ago for the treatment of patients with advanced non-small cell lung cancer (NSCLC), following failure on at least 1 prior chemotherapy treatment.

The FDA has approved the first ever blood-based companion diagnostic test. The cobas EGFR Mutation Test v2 was developed by Roche for the drug erlotinib (Tarceva), which was developed by Astellas ...

Erlotinib should be available on the NHS within 3 months of the guidance being issued. If you are already taking erlotinib or gefitinib for non‑small‑cell lung cancer, that is not recommended above, ...

Loss of heterozygosity predicted increased risk for oral cancer among patients with oral premalignant lesions, according to the results of a randomized clinical trial.Although loss of ...

FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung Cancer Tarceva is the First Personalized Medicine Approved for the Initial Treatment of People with ...